NEOGENOMICS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NEOGENOMICS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $314.29M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $290.10M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $244.60M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $187.90M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $187.06M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $185.89M | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | $49.92M | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $50.83M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | $48.97M | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | $47.12M | Feb 28, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($108.03M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($78.73M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | ($87.97M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | ($144.25M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | ($8.35M) | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $4.17M | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | $6.30M | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $2.14M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | $1.99M | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | ($2.42M) | Feb 28, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($115.88M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($92.11M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | ($107.74M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | ($157.62M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | ($118.75M) | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | ($13.99M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $13.01M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $10.04M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $2.90M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $2.16M | Feb 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.08M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $31.16M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $27.31M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $30.33M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $21.87M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $8.23M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $8.49M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $3.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $3.64M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $4.65M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.23M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $7.02M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | ($1.95M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | ($65.99M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | ($26.72M) | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $1.46M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $23.37M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $44.79M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $18.04M | Feb 28, 2020 |
| FY2013 | Dec 31, 2013 | $2.23M | Feb 24, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.01M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $41.06M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $28.75M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $30.89M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $64.14M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $29.10M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $20.03M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $14.31M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $13.69M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $7.54M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.64B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.68B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.74B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $1.87B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $988.33M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $709.51M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $505.02M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $344.45M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $337.12M | Mar 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $523.27M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $735.70M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $739.69M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $742.01M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $761.50M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $294.04M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $202.10M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $184.57M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $139.88M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $150.52M | Mar 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $836.56M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $902.34M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $941.54M | Feb 17, 2026 |
| FY2025 | Dec 31, 2022 | $998.02M | Feb 17, 2026 |
| FY2024 | Dec 31, 2021 | $1.11B | Feb 18, 2025 |
| FY2023 | Dec 31, 2020 | $694.29M | Feb 20, 2024 |
| FY2022 | Dec 31, 2019 | $507.41M | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | $320.44M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $171.96M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $162.32M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $524.34M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $522.77M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $522.77M | Feb 17, 2026 |
| FY2023 | Dec 31, 2022 | $522.77M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $527.12M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $211.08M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $198.60M | Feb 25, 2021 |
| FY2020 | Dec 31, 2018 | $197.89M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $147.02M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $147.02M | Feb 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($433.81M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($325.78M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | ($247.06M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | ($159.09M) | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | ($14.84M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($7.19M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($11.36M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($19.36M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($58.42M) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($52.46M) | Mar 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $159.62M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $367.01M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $342.49M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $263.18M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $316.83M | Feb 24, 2023 |
| FY2022 | Dec 31, 2020 | $228.71M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $173.02M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $9.81M | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | $12.82M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $12.53M | Feb 26, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $341.86M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $541.11M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $538.20M | Feb 18, 2025 |
| FY2018 | Dec 31, 2018 | $101.75M | Feb 26, 2019 |
| FY2017 | Dec 31, 2017 | $96.65M | Mar 13, 2018 |
| FY2016 | Dec 31, 2016 | $97.90M | Mar 14, 2017 |
| FY2015 | Dec 31, 2015 | $55.02M | Apr 18, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | 0 | Apr 18, 2016 |
| FY2015 | Sep 30, 2015 | 0 | Apr 18, 2016 |
| FY2015 | Jun 30, 2015 | 0 | Apr 18, 2016 |
| FY2015 | Mar 31, 2015 | 0 | Apr 18, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Apr 18, 2016 |
| FY2015 | Sep 30, 2014 | 0 | Apr 18, 2016 |
| FY2015 | Jun 30, 2014 | 0 | Apr 18, 2016 |
| FY2015 | Mar 31, 2014 | 0 | Apr 18, 2016 |
| FY2013 | Dec 31, 2013 | 0 | Feb 24, 2014 |
| FY2013 | Sep 30, 2013 | 0 | Feb 24, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | 0 | Apr 18, 2016 |
| FY2015 | Sep 30, 2015 | 0 | Apr 18, 2016 |
| FY2015 | Jun 30, 2015 | 0 | Apr 18, 2016 |
| FY2015 | Mar 31, 2015 | 0 | Apr 18, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Apr 18, 2016 |
| FY2015 | Sep 30, 2014 | 0 | Apr 18, 2016 |
| FY2015 | Jun 30, 2014 | 0 | Apr 18, 2016 |
| FY2015 | Mar 31, 2014 | 0 | Apr 18, 2016 |
| FY2013 | Dec 31, 2013 | 0 | Feb 24, 2014 |
| FY2013 | Sep 30, 2013 | 0 | Feb 24, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 128.15M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 128.15M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 127.37M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 126.91M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | 124.11M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 112.08M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 104.78M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 94.47M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 80.46M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 78.57M | Mar 13, 2018 |